Journal article icon

Journal article

Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.

Publication status:
Published

Actions


Access Document


Publisher copy:
10.1016/j.ctrv.2004.06.005

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Trial Service Unit
Journal:
Cancer treatment reviews
Volume:
30
Issue:
6
Pages:
583-588
Publication date:
2004-10-05
DOI:
EISSN:
1532-1967
ISSN:
0305-7372
URN:
uuid:a343d0ac-9b1e-4485-8b36-50253187fd63
Source identifiers:
66446
Local pid:
pubs:66446
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP